CA2836769C - The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder - Google Patents

The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder Download PDF

Info

Publication number
CA2836769C
CA2836769C CA2836769A CA2836769A CA2836769C CA 2836769 C CA2836769 C CA 2836769C CA 2836769 A CA2836769 A CA 2836769A CA 2836769 A CA2836769 A CA 2836769A CA 2836769 C CA2836769 C CA 2836769C
Authority
CA
Canada
Prior art keywords
aryl
another embodiment
substituted
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2836769A
Other languages
English (en)
French (fr)
Other versions
CA2836769A1 (en
Inventor
Yi Liu
Pingda Ren
Katayoun JESSEN
Xin Guo
Christian Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Intellikine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellikine LLC filed Critical Intellikine LLC
Publication of CA2836769A1 publication Critical patent/CA2836769A1/en
Application granted granted Critical
Publication of CA2836769C publication Critical patent/CA2836769C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2836769A 2011-05-04 2012-05-04 The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder Active CA2836769C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482568P 2011-05-04 2011-05-04
US61/482,568 2011-05-04
PCT/US2012/036688 WO2012151562A1 (en) 2011-05-04 2012-05-04 Combination pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
CA2836769A1 CA2836769A1 (en) 2012-11-08
CA2836769C true CA2836769C (en) 2018-11-13

Family

ID=47108075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836769A Active CA2836769C (en) 2011-05-04 2012-05-04 The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder

Country Status (7)

Country Link
US (2) US20140357651A1 (enExample)
EP (1) EP2705181B1 (enExample)
JP (1) JP6047149B2 (enExample)
CN (1) CN103703174B (enExample)
CA (1) CA2836769C (enExample)
ES (1) ES2618489T3 (enExample)
WO (1) WO2012151562A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
ES2618489T3 (es) 2011-05-04 2017-06-21 Intellikine, Llc Composiciones farmacéuticas combinadas y usos de las mismas
CN103796655A (zh) * 2011-05-06 2014-05-14 加利福尼亚大学董事会 多囊性疾病的治疗
WO2014153509A1 (en) * 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015002766A1 (en) 2013-07-02 2015-01-08 Nikolai Khodarev Anti-tumor therapy
US10112962B2 (en) 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
WO2016103190A1 (en) * 2014-12-24 2016-06-30 The University Of North Carolina At Chapel Hill Combined local delivery of therapeutic agents using interventional devices and radiation
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
RS63609B1 (sr) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
EP3442980B1 (en) 2016-04-15 2021-06-09 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
EP3522887A4 (en) * 2016-10-07 2020-06-10 Abraxis BioScience, LLC METHODS OF TREATING BILARIAN CANCER
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CN118978535A (zh) 2018-05-01 2024-11-19 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JP7668536B2 (ja) * 2020-02-07 2025-04-25 範行 東 細胞周期のｇ１期初期制御剤
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
KR20230039675A (ko) 2020-07-13 2023-03-21 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045676A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
RU2538683C2 (ru) * 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
ES2618489T3 (es) 2011-05-04 2017-06-21 Intellikine, Llc Composiciones farmacéuticas combinadas y usos de las mismas

Also Published As

Publication number Publication date
CA2836769A1 (en) 2012-11-08
US20140357651A1 (en) 2014-12-04
HK1195793A1 (en) 2014-11-21
US10172858B2 (en) 2019-01-08
US20160287595A1 (en) 2016-10-06
WO2012151562A1 (en) 2012-11-08
JP6047149B2 (ja) 2016-12-21
EP2705181A4 (en) 2014-10-08
ES2618489T3 (es) 2017-06-21
JP2014513138A (ja) 2014-05-29
EP2705181B1 (en) 2016-12-21
EP2705181A1 (en) 2014-03-12
CN103703174B (zh) 2017-05-10
CN103703174A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
US10172858B2 (en) Combination pharmaceutical compositions and uses thereof
US20170209448A1 (en) Treatment regimens using multiple pharmaceutical agents
US9295673B2 (en) Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9682141B2 (en) Combination of kinase inhibitors and uses thereof
WO2014151147A1 (en) Combination of kinase inhibitors and uses thereof
JP6749858B2 (ja) 複素環式化合物およびそれらの使用
US20160089371A1 (en) Combination of Kinase Inhibitors and Uses Thereof
CA2856803A1 (en) Enhanced treatment regimens using mtor inhibitors
WO2012154608A1 (en) Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2012154610A1 (en) Reactive pi3k kinase inhibitors and uses thereof
HK1195793B (en) Combination pharmaceutical compositions and uses thereof
HK1236441A1 (zh) 激酶抑制劑的組合及其用途
HK1236441A (en) Combination of kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170418

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250416

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260430